Can Basal Cell Carcinoma Come Back in the Same Spot?

Basal cell carcinoma can absolutely come back in the same spot after treatment, and it does so more often than many people expect. While surgical removal cures most cases, studies report local recurrence rates ranging from about 2% after Mohs micrographic surgery to well over 10% after standard excision, depending on the tumor’s features and location. What makes recurrence tricky is that it doesn’t always show up quickly, and a returning BCC often behaves more aggressively than the original.

How Often BCC Comes Back

The recurrence rate depends heavily on the type of treatment and the tumor itself. In one retrospective study of patients followed for at least three years after surgical excision, the recurrence rate was about 6%.¹ But that number can climb much higher when tumor margins aren’t clear. When a BCC is incompletely excised, meaning the surgeon didn’t get all of it based on pathology, roughly a third of those cases come back. One study followed 90 incompletely excised BCCs for a median of about five years and found recurrence in 32%.² Other literature puts the range for positive-margin cases between 10% and 67%, depending on additional risk factors.³

Even when a surgeon re-excises a BCC that had positive margins, residual tumor is found surprisingly often. One analysis of 184 incompletely excised BCCs found that among the 62 that underwent re-excision, about 63% still had residual tumor in the specimen.⁴ That finding underscores why positive margins are taken seriously and why follow-up matters even after a second operation.

What Makes Recurrence More Likely

Several features of the original tumor make it more prone to coming back. A large study of over 700 BCCs found that tumor size, location in the central face (the so-called “H zone,” covering the nose, inner eye area, ears, and temples), younger age at diagnosis, and aggressive histological subtypes all showed a statistically significant link to recurrence.⁵ The H zone matters because skin structures are packed tightly there, making it harder to achieve wide margins without damaging important anatomy.

Aggressive subtypes deserve special attention. Morpheaform (also called sclerosing) BCC has finger-like projections that extend beyond the visible borders of the tumor, which makes complete removal difficult. In a study of incompletely excised BCCs in the head and neck, the morpheaform type carried a relative risk of recurrence nearly 1.7 times higher than other subtypes, and scalp location pushed the relative risk even higher, to about 2.3 times.⁶ Tumors larger than 2 cm and those that had already recurred once also faced elevated risk in the same analysis.

Perineural invasion, where tumor cells grow along or around nerves, is another worrying feature. Tumors with perineural involvement tend to be larger and require more extensive surgery. In one series of BCCs treated with Mohs surgery, tumors with perineural invasion required an average of 5.3 surgical stages for clearance compared to 2.2 stages for those without, and the final wound after surgery was dramatically larger.⁷ Perineural invasion also tends to show up in larger, higher-risk tumors and those invading deeper into the skin.⁸ Interestingly, though, at least one matched-cohort study found that perineural invasion of small unnamed nerves did not independently change local recurrence or disease-specific outcomes, suggesting the picture is nuanced and the significance may depend on which nerves are involved.⁹

When Recurrence Tends to Show Up

One of the more unsettling aspects of BCC recurrence is that it can take years. A classic analysis found that fewer than a third of all recurrences appear within the first year after treatment, and only about half show up within two years. By three years, about two-thirds of recurrences have been detected. But roughly 18% of recurrences don’t surface until somewhere between year five and year ten. A useful rule of thumb from this research: the ten-year recurrence rate is roughly double the two-year rate.¹⁰

When a tumor that has already recurred once is treated again, the timeline can shift. One study found that the median time to detecting recurrence was about 1.3 years for previously recurrent tumors, compared to about 3.9 years for tumors being treated for the first time.¹¹ In the same study dealing with incompletely excised head-and-neck BCCs, the average interval to recurrence was about 20 months.⁶ The message is that short-term clearance doesn’t guarantee long-term cure, and follow-up visits years after treatment are not overkill.

How Treatment Choice Affects Recurrence

Surgery remains the standard treatment because it allows pathologists to check whether the tumor was fully removed, and it carries the lowest recurrence rates overall.¹² But not all surgical approaches are equal when it comes to keeping BCC from returning.

Mohs micrographic surgery, in which the surgeon maps and examines 100% of the tissue margin during the procedure, performs best. A comprehensive review of all studies since 1945 on the treatment of recurrent BCC found a five-year recurrence rate of about 5.6% with Mohs, compared to roughly 17% for standard excision, about 10% for radiation therapy, and 40% for curettage and electrodesiccation.¹³ That near-fourfold difference between Mohs and non-Mohs methods makes a strong case for Mohs when treating a BCC that has already come back once.

A randomized controlled trial comparing Mohs to standard excision for facial BCC showed that for primary tumors, recurrence rates were low for both (about 2% for Mohs vs 3% for standard excision), with no statistically significant difference.¹⁴ With longer follow-up, the advantage of Mohs became clearer for recurrent tumors specifically: about 2.4% re-recurred after Mohs versus roughly 12% after standard excision, a statistically significant difference.¹⁵

Non-surgical options carry higher recurrence rates in general. Curettage and photodynamic therapy had five-year relapse rates as high as 70% in one real-world analysis, compared to much lower rates with excision and radiotherapy.¹⁶ That doesn’t mean non-surgical options are always wrong. For small, low-risk, superficial BCCs, treatments like topical imiquimod, photodynamic therapy, and cryotherapy are considered reasonable alternatives.¹⁷ For superficial and nodular BCCs around the eye, a systematic review found that imiquimod produced durable local control in tumors that responded, with no relapses noted in a small randomized trial over 24 months.¹⁸ The key is matching the treatment to the risk profile. High-risk or recurrent tumors are not good candidates for these lighter-touch methods.

Is It Really a Recurrence, or a New Tumor?

This is a question that even clinicians wrestle with. When a BCC appears near a previous treatment site, it may be residual disease that wasn’t fully cleared, or it may be an entirely new cancer arising in sun-damaged skin nearby. One study examined supposed “recurrences” after complete conventional excision and found that two-thirds of the possible recurrences occurred in the temple and forehead, even though those sites represented only about 22% of all lesions. The authors suggested many of those were likely new primaries growing in an area of field change rather than true residual disease.¹⁹

The distinction matters practically. A true recurrence means the original tumor wasn’t fully eradicated and the remaining cells continued to grow. It tends to be more aggressive, often deeper, and can adopt a more infiltrative growth pattern within scar tissue. A new primary, while still needing treatment, starts fresh and is generally easier to manage. The problem is that telling them apart under the microscope is difficult. Scar tissue from a prior excision can disrupt a recurrent tumor’s growth pattern, making it grow in discontinuous nests rather than as a solid mass.²⁰ Scar tissue can also mimic the appearance of an aggressive subtype on biopsy, potentially leading to over-staging.²¹

How Recurrent BCC Is Treated

When a BCC does come back, the treatment philosophy shifts. A first-time BCC has well-defined borders in tissue that hasn’t been operated on before, making it relatively straightforward to remove. A recurrent tumor grows within scar tissue where the tissue planes are distorted, and its margins are harder to see clinically and microscopically. This is why Mohs surgery is widely considered the treatment of choice for recurrent BCC. The five-year re-recurrence rate of about 5.6% with Mohs compares favorably to nearly 20% with non-Mohs methods for previously treated tumors.¹³

For patients who aren’t surgical candidates, options still exist. Radiation therapy offers a reasonable alternative, particularly for older patients or those with tumors in difficult locations. When a recurrent BCC becomes locally advanced and can’t be managed with surgery or radiation, systemic therapies come into play. Hedgehog pathway inhibitors like vismodegib and sonidegib were developed specifically to target the molecular pathway that drives most BCCs.²² More recently, the immune checkpoint inhibitor cemiplimab was approved for patients whose advanced BCC has progressed on or can’t tolerate a hedgehog inhibitor.²³ Case reports have documented complete responses using these agents even in difficult, multiply-recurrent tumors.²⁴

Follow-Up Schedules After Treatment

Given the long window over which recurrences can appear, follow-up is not optional. A systematic review of clinical practice guidelines found that most recommend visits every 6 to 12 months for low-risk BCC. For high-risk tumors, some guidelines recommend visits as often as every 3 months, with most settling on every 6 months.²⁵ The duration of surveillance varies widely across guidelines, from a single post-treatment visit to lifelong monitoring. Given that nearly one in five recurrences doesn’t surface until five to ten years out, a single post-treatment check is clearly insufficient for any tumor with risk factors.

What you’re looking for between visits is any new growth, change in texture, or non-healing area at or near the treatment site. Recurrent BCCs often appear as a small translucent or pearly bump within or near the scar, sometimes with tiny blood vessels visible on the surface. They can also look like a flat, slightly shiny patch that seems to be slowly expanding. Any change in a scar that was previously stable warrants a dermatologist’s evaluation.

Immunosuppression and Higher Risk

If you’re on immunosuppressive medication, such as after an organ transplant, your risk picture changes. Organ transplant recipients develop BCC at a higher rate than the general population, and there’s evidence that their tumors behave more aggressively. A clinicopathologic comparison found that BCCs in transplant recipients showed a greater prevalence of deep invasion, even among tumors that were completely excised.²⁶ The immune system plays a role in keeping residual cancer cells in check, so when that surveillance is suppressed, even small remnants are more likely to regrow.

Interestingly, the recurrence rates after specific treatments may not differ as dramatically as you’d expect. One study comparing photodynamic therapy outcomes found a recurrence rate of about 23% in organ transplant recipients versus about 15% in the general population, a difference that did not reach statistical significance.²⁷ Still, the overall burden of skin cancers in immunosuppressed patients is higher, and these individuals are typically monitored more frequently.

The Cost Question Around Mohs

If Mohs surgery is the best option for recurrent BCC, you might wonder why it’s not used for every case. Part of the answer is cost. An economic analysis found that the total treatment costs of Mohs are significantly higher than standard excision, and for primary BCC, the cost per additional cure was substantial enough that Mohs didn’t appear cost-effective on a population level.²⁸ The ratio looked more favorable for recurrent tumors, since the higher cure rate offsets more of the added expense. In practice, Mohs tends to be reserved for high-risk situations: tumors on the face, recurrent tumors, aggressive subtypes, and areas where tissue conservation matters for cosmetic or functional reasons. For a straightforward, small BCC on the trunk, standard excision is usually perfectly adequate.

The morpheaform subtype illustrates this tradeoff well. Even after complete excision, morpheaform BCC carries about a 3.8% recurrence rate, which is notably higher than for more common nodular types.²⁹ For these tumors, the added precision of Mohs is generally considered well worth the extra cost, particularly in cosmetically sensitive areas like the face.

Emerging Approaches for Difficult Cases

Some patients face situations where conventional treatments run out of road. Multiply recurrent BCC in a location that has been operated on multiple times can become inoperable, either because there’s not enough tissue left for another surgery or because the patient’s health won’t allow it. In these cases, newer systemic treatments are expanding options. Hedgehog inhibitors and PD-1 checkpoint inhibitors have shown significant activity against advanced BCC.²⁴ One case report documented the complete eradication of a recurrent, infiltrative, and sclerosing BCC on the upper lip using a three-month course of vismodegib alone.³⁰

Even more experimental approaches are emerging. A recent case report described a patient with multiple painful, recurrent ulcerative BCCs who could not undergo further surgery or radiation. A topical methylene blue gel formulation was applied, and both the recurrent and a nodular BCC healed completely, with no recurrence after one year of follow-up.³¹ This is a single case and far from standard practice, but it reflects the active search for solutions when the usual tools no longer work. The broader point is that even when BCC keeps returning, the treatment landscape continues to expand, and truly untreatable cases are becoming rarer.